%PDF-1.7 % 12 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20191019001823-04'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 13 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /Annots [ 7 0 R 8 0 R ] /PZ 1 >> endobj 13 0 obj <> stream x\r8}Wte*h;xLݪ<$$bB ~~v Mr* SZnu//OU:89'<|| ;?p?3z΍J 0':< };p407^l~?tcyj25"] }'8 =' cZxkZ+6SfK޴vTp~F\AyTj@KiшK`)*p@d7 N_,j'{ͮ}Љ2\,pK¯wqLC:Ie~A, [׫7eYψ2ʼn㢩ߘy JΊ#-7^3%Z`lLXSlE`'Tu+8.juL]L Z+^@lPǰ? C, 4L׼ Wl"T9Tz]|E>d~d xׂ#p[jRd\kI h+\2]*vա<j0ۚг5VKTwz :)W 觨-XwhKtYEE)qkj^ j˒6w%.pSTêokK/L9c|mvI3N xy yDۻQ*wȰԲS,D3Nl~Bh%[&?\dhXJjY d$c"mR`x(UWxu8X7{tKnؗ¹#ה24좏Zb`"߮v2Пk9Rٛ1ǮM̯mAc 66te-L$?vm a¥$ dKcȸq=sFzUn ׬ 7l-kHBfiKyM"wߤ~{0gD_2+5ߝt ؞:a= F8I7H?9Ad^?33/$vν3wkZ.9"ѥhV+Zye/lwx HcXsۍ>f۪Pt]VXyF }n#UFXͦg߽Ӿn=1i%u?/^jHgI5Soh @{T,C=ǘ݌=m4TڬE# ]t9z(vG;ExCh٦3Y6pF xtpE2`hJgKhh(bkXv.%WJ6P+AkӲ0CSDMs_BqU+)w*ڣ Léٖ+]v ~v|Rkowٮ6dZ%Ox._3G~zz& \<~8'R߽`CZ׊GB$t=uc@N=-! Bir pKfDfjfEɧlÉzl3`"lV;zFߖK QplqFW^36kH-8mnK7 MKd2:d/p nK[A^\6`ܒ)fV+4lNFg )dԽ᜼7\NB9|h):>LKIj:Drѐ5j ZiEo{uz eSOs8hl)PI6u?ء:iWb%0t4܅ˁF4rL!ǽ5l?5٠0 n8OfR6 SYBkN; dM1M)4ЄA(6K+4ru_0m1Eb9J1A 78uX=-jA?Qlٰ/ilNP`0;'r%>\qu1{2C;惤A``ǹ&ͦBûU97₭pUs 4qݑfꍙU40=jgFI-$Dž9H۷ kV8[LX^ ~e {t;#Ae7shk5;g=z음rA`M.wm̏TWR*.7V ڝ1OXqS_c;֍v> /Annots [ 9 0 R 10 0 R 11 0 R ] /PZ 1 >> endobj 15 0 obj <> stream xV[O0~8C"ع`LBL-4q&KB6WM"bJOA .Js|W|3F/lmBD=~Ixi4|\?܂x;{qχ$E Uz%Cz/G]6%y.{!6~met inwlz9#<@SHT \gq%L)>(F&Eդ,6 zbd!cHTZcY:.0TήCmv =D UnPpko-œH{b@h@N! aRp}+ac*)2cE*xԢH~!ߜEU6c-xT6Nnc!{>C+`^t;Iq.'tE RLrQM<ĀQr(3N_q).Rw|G D 'R˧؈y"q$;B-TshjK!0*$ji251-ZKcDй*, "P6s}IhЖ>z,W,I>_V:ue~j` ItH-nlce/x_W, my}xa׹9q-ȁs`wnxvX3́>8z/p̳ endstream endobj 1 0 obj << /Type /Pages /Kids [ 12 0 R 14 0 R ] /Count 2 >> endobj 3 0 obj <> endobj 5 0 obj <> endobj 6 0 obj <> endobj 16 0 obj <> stream JFIFHHExifMM* z(1>?QQ Q HHPaint.NET v3.5.10z%u0`:oCC." }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?(f 1T$`9Sw(B@;~(]Cd꾫Es:aݻd2\(2F][&]ۢϲ|W͵L@A A 8 (CĝCglZE/ |Ezє{ xQʒ@[ྊ\/I4R0?6.7`ŴwPu|3/Z@Ogi}cFdFKoj?~8|p_A<ĺOkGPK $wRmkmF;YVx&rLj#p ׭axf|s$Ӿc:Qwm]N)Cψ[eYba98xB+oTÚwcRþ$U[ ?qΙ{&jv6Xo$=ԗ&7zgAxIִ.$3,mwc{+%g[!U@&Fϻm/#hci'7n[%It.&/ֶ+Zl~:wi~D>$}o+}@.[/+B6mnt8bi{zc.~F{eUe86g3 VT&> BK VؘXzSMesoM_&ϔIÍK?+hڿnt_ K]H '̽yrWA=O+|"!gɤItXe>Xs hwwG Eouqa /ş_~~'x} ]_^]/ 蚼:<cu/ h&omEۯicǪ\[,k}_uS}㏆W]G^tmf`Ks ]=va&h9n忔>75NWQτ0of,E (˰8hBC_ Jq'W UQKz,N>+`S%}b5ISJ]+(&QVN>eoy7xG4[]]3K{i$I>g-(mbynLIC,"*3f?-%`lfPx涽X"H'h"ֈ(TfeU:܉,a,R*I4xcxalOhGр|ia$cg,{gAHEu->]F,{-.,EX"I$XQD/3R.{{T&ҭ%4[OPnx"HhM :e}-Լ'=s:\iZ<+Lj5+1AɮLZx-☽G3 1I"kuχ+A}5'NxI8 gJk[oenm!x,=n=>}kjPx~M񧍼5k45a,RLiȖTFQMR&K;}r+XkY[y>2F=2~6>Gmi++<[WF76MH4>;;Kf۽ъM3ZE}c㿈*- -.|G5uI![ YR$$A>Eyׇ|7u;n>4׭JϷR[h!rVr\{~Ϛ >0jMg?_y_ Do/x;ÚƏi a𶕦f|Eqgk4V^RY]}F,/J%ՌAud%:x3Hg_4[+^ ҴKaXF'n.]Z(i$bef5GO:u]/a~.3N4xiG*a8ާ-U){G nJEڿ[m7wv5MYp|'gm # #%B?|鿲w­{+_|Q#VkxcZޛ{I]Wyak}..i˨iY9QwOA~hf{+ |Y;cڴ27G>|H,na8o; CEO,ZLP?SHK} e92W7/1aj¤aڄq4 қS7,5]%EƔc/uҒw\r/EnT y>!V+VK4X^Y{;+Ӫ=MqslEn?Zz'Ë}^2xĺGf70/M~*DU=坍G{wwvci%vZ$GY&J9dkՀ\6hs.F*ĩ"+S%s*{ qqDj3$ q^T24,Cn +=j񟍼q5k'\%ݎ{ͦuyq4X$y<ك2Ey%™|Icw]3#R[`{KցY [1*kLOdw ^OAkЏb<¿ <=6x0ׄ>(=*[ t]9-?IZ@}/>FۃQ@ endstream endobj 4 0 obj << /Type /XObject /Subtype /Form /FormType 1 /Filter /FlateDecode /BBox [0.000000 0.000000 595.276000 76.535433] /Matrix [1 0 0 1 0 0] /Resources << /ProcSet [/PDF /Text /ImageB /ImageC /ImageI] /Font << /F2 5 0 R /F1 3 0 R >> /XObject << /I0 16 0 R >> >> /Length 197 >> stream xKkBA WeI&ڊU/ nʥBf8A3!(X4`JQj*Aj͕197f hkL[=µrw]F D%x2WC0 9)Z ^Wh}29yyu?4g=bT1߻a endstream endobj 2 0 obj << /ProcSet [/PDF /Text /ImageB /ImageC /ImageI] /Font << /F1 3 0 R /F2 5 0 R /F3 6 0 R >> /XObject << /XT4 4 0 R /I0 16 0 R >> >> endobj 7 0 obj <> /H /I>> endobj 8 0 obj <> /H /I>> endobj 9 0 obj <> /H /I>> endobj 10 0 obj <> /H /I>> endobj 11 0 obj <> /H /I>> endobj 17 0 obj << /Title (Phase 3 study strengthens support of ibrutinib as second-line therapy for CLL) /Subject (Phase 3 study strengthens support of ibrutinib as second-line therapy for CLL) /Creator (Science X Network) /Producer (TCPDF 6.2.25 \(http://www.tcpdf.org\)) /CreationDate (D:20191019001823-04'00') /ModDate (D:20191019001823-04'00') /Trapped /False >> endobj 18 0 obj << /Type /Metadata /Subtype /XML /Length 4395 >> stream application/pdf Phase 3 study strengthens support of ibrutinib as second-line therapy for CLL Phase 3 study strengthens support of ibrutinib as second-line therapy for CLL 2019-10-19T00:18:23-04:00 Science X Network 2019-10-19T00:18:23-04:00 2019-10-19T00:18:23-04:00 TCPDF 6.2.25 (http://www.tcpdf.org) uuid:86112deb-ac0b-6941-74cc-840109c328f6 uuid:86112deb-ac0b-6941-74cc-840109c328f6 http://ns.adobe.com/pdf/1.3/ pdf Adobe PDF Schema http://ns.adobe.com/xap/1.0/mm/ xmpMM XMP Media Management Schema internal UUID based identifier for specific incarnation of a document InstanceID URI http://www.aiim.org/pdfa/ns/id/ pdfaid PDF/A ID Schema internal Part of PDF/A standard part Integer internal Amendment of PDF/A standard amd Text internal Conformance level of PDF/A standard conformance Text endstream endobj 19 0 obj << /Type /Catalog /Version /1.7 /Pages 1 0 R /Names << >> /ViewerPreferences << /Direction /L2R >> /PageLayout /SinglePage /PageMode /UseNone /OpenAction [12 0 R /FitH null] /Metadata 18 0 R >> endobj xref 0 20 0000000000 65535 f 0000004663 00000 n 0000011198 00000 n 0000004730 00000 n 0000010697 00000 n 0000004836 00000 n 0000004947 00000 n 0000011344 00000 n 0000011588 00000 n 0000011832 00000 n 0000012119 00000 n 0000012406 00000 n 0000000015 00000 n 0000000491 00000 n 0000003328 00000 n 0000003812 00000 n 0000005061 00000 n 0000012624 00000 n 0000013206 00000 n 0000017684 00000 n trailer << /Size 20 /Root 19 0 R /Info 17 0 R /ID [ <86112debac0b694174cc840109c328f6> <86112debac0b694174cc840109c328f6> ] >> startxref 17894 %%EOF